Slayback Pharma has championed the US Food and Drug Administration’s competitive generic therapy pathway after receiving approval for an AB-rated generic version of Allergan’s Taytulla (norethindrone acetate/ethinyl capsules; ferrous fumarate capsules) with the CGT designation, “less than eight months from filing.”
Final approval for Slayback’s abbreviated new drug application product, named Merzee, with a CGT designation brings the potential of 180 days of exclusivity, with the New
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?